Insider Trading Activity Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Director Bought 108,601 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Andrew N Schiff , Director of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) reportedly Bought 108,601 shares of the company’s stock at an average price of 23.02 for a total transaction amount of $2,499,995.02 SEC Form

Insider Trading History For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

On 10/7/2015 Vivo Ventures Vii, Llc, Major Shareholder, bought 13,352 with an average share price of $11.00 per share and the total transaction amounting to $146,872.00.View SEC Filing

On 10/8/2015 Ra Capital Management, Llc, Major Shareholder, bought 2,237,130 with an average share price of $10.86 per share and the total transaction amounting to $24,295,231.80.View SEC Filing

On 10/13/2015 Sofinnova Venture Partners Vii, Major Shareholder, bought 409,090 with an average share price of $11.00 per share and the total transaction amounting to $4,499,990.00.View SEC Filing

On 10/13/2015 Fmr Llc, Insider, bought 335,455 with an average share price of $11.00 per share and the total transaction amounting to $3,690,005.00.View SEC Filing

On 10/13/2015 Albert Cha, Director, bought 454,545 with an average share price of $11.00 per share and the total transaction amounting to $4,999,995.00.View SEC Filing

On 10/14/2015 Ra Capital Management, Llc, Major Shareholder, bought 42,813 with an average share price of $14.06 per share and the total transaction amounting to $601,950.78.View SEC Filing

On 10/21/2015 Ra Capital Management, Llc, Major Shareholder, bought 34,999 with an average share price of $14.89 per share and the total transaction amounting to $521,135.11.View SEC Filing

Analyst Ratings For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
These are 5 Buy Ratings .
The current consensus rating for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is Buy (Score: 3.00) with a consensus target price of $40.00 , a potential (50.43% upside)

Analyst Ratings History For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

On 11/2/2015 William Blair Initiated Coverage of rating Outperform with a price target of $30.00
On 3/16/2016 Citigroup Inc. Lower Price Target of rating Buy with a price target of $34.00 to $29.00
On 9/30/2016 JMP Securities Initiated Coverage of rating Outperform with a price target of $34.00
On 11/29/2016 Leerink Swann Initiated Coverage of rating Outperform
On 7/4/2017 Guggenheim Reiterated Rating Buy with a price target of $40.00
On 7/31/2017 Jefferies Group LLC Reiterated Rating Buy with a price target of $36.00
On 8/9/2017 Cantor Fitzgerald Set Price Target of rating Buy with a price target of $50.00

Recent Trading Activity for Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Shares of Aclaris Therapeutics, Inc. closed the previous trading session at 26.59 down -0.31 -1.15% with 167,384 shares trading hands.